ranolazine (Ranexa)

Advice

following a second resubmission

ranolazine (Ranexa®) is not recommended for use within NHS Scotland.

Indication under review: as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).

When added to standard doses of antianginal drugs, ranolazine increased exercise duration at trough drug levels compared with placebo after 12 weeks treatment.  Although significant the effect size was modest.

The submitting company did not present a sufficiently robust clinical and economic case to gain acceptance by SMC.